1. Articles from Sanmartín E , et al.

    1-2 of 2
    1. Deletion of 11q in neuroblastomas drives sensitivity to PARP inhibition.

      Deletion of 11q in neuroblastomas drives sensitivity to PARP inhibition.

      Clin Cancer Res. 2017 Aug 22;:

      Authors: Sanmartín E, Muñoz L, Piqueras M, Sirerol JA, Berlanga P, Cañete A, Castel V, Font de Mora J

      Abstract PURPOSE: Despite advances in multimodal therapy, neuroblastomas with hemizygous deletion in chromosome 11q (20-30%) undergo consecutive recurrences with poor outcome.

      Read Full Article
    2. TIAM1 variants improve clinical outcome in neuroblastoma.

      TIAM1 variants improve clinical outcome in neuroblastoma.

      Oncotarget. 2017 Apr 03;:

      Authors: Sanmartín E, Yáñez Y, Fornés-Ferrer V, Zugaza JL, Cañete A, Castel V, Font de Mora J

      Abstract Identification of tumor driver mutations is crucial for improving clinical outcome using a personalized approach to the treatment of cancer.

      Read Full Article
      Mentions: Treatment ALK MYCN
    1-2 of 2
  1. Categories

    1. Research:

      Cancer Cell, Case Report, Cells and Stem Cells, Clinical Research, Conferences, Disease Classification, Drug, Drug Delivery, Drug Resistance, Epigenetics and Epigenomics, General, Genetics, Genomics, Guidelines, Immune Therapy, Induction, Long Term Effects, Low / Intermediate Risk, Nanotechnology, Olfactory Neuroblastoma, Onco-Fertility, Oncogenesis, Other Cancers, Personalized Medicine, Pharma, Pre-Clinical, Prognostics, PubMed, Review, Small Molecules, Surgery, Survivorship, Trials, Tumor Biology, Virotherapy
    2. Business:

      Funding, IP, Pharma
    3. Non-Profit:

      Advocacy, Charity, Events, Foundation, Funding, Human Interest
    4. Press Release:

      Announcement, News, Pharma
    5. General:

      Adolescent and Young Adults, Bioethics, Blog, Burden of Treatment, Children & Families, Diagnosis and Detection, Drug Development, Epidemiology, Imaging, Incidence, Information, News, Overview of the Disease, Pain Control, Palliative Care, Psychosocial, Regulation, Side-Effects, Social, Supportive Care, Treatment
    6. Media:

      Audio, Blogs, Video
  2. Topics in the News

    1. (1 articles) ALK
    2. (1 articles) MYCN
    3. (1 articles) Treatment
  3. Popular Articles

  4. Picture Gallery

    Too many cancer drugs? Crowded market gives investors pause Targeted Doxorubicin-Loaded Bacterially Derived Nano-Cells for the Treatment of Neuroblastoma Reducing number of tumour-supporting cells to fight neuroblastoma Clinical Trial of Arsenic Trioxide Combined Chemotherapy in the Treatment of Stage 4 Neuroblastoma Tumorigenic and Antiproliferative Properties of the TALE-Transcription Factors MEIS2D and MEIS2A in Neuroblastoma Children with Non-chromosomal Birth Defects Face Higher Risk of Several Childhood Cancers PIM Kinases Are a Potential Prognostic Biomarker and Therapeutic Target in Neuroblastoma Childhood cancer survivors may develop heart problems sooner New biomarkers for neuroblastoma, a type of cancer in children Autolus’ solid tumour CAR-Ts will have ‘off switch’ Antibody-Drug Conjugate Field Expanding in Oncology Epigenetic analysis: Giving the right name to a tumor